220 related articles for article (PubMed ID: 25695222)
21. A nationwide retrospective study of perioperative chemotherapy for gastroesophageal adenocarcinoma: tolerability, outcome, and prognostic factors.
Larsen AC; Holländer C; Duval L; Schønnemann K; Achiam M; Pfeiffer P; Yilmaz MK; Thorlacius-Ussing O; Bæksgaard L; Ladekarl M
Ann Surg Oncol; 2015 May; 22(5):1540-7. PubMed ID: 25348777
[TBL] [Abstract][Full Text] [Related]
22. Study to determine adequate margins in radiotherapy planning for esophageal carcinoma by detailing patterns of recurrence after definitive chemoradiotherapy.
Button MR; Morgan CA; Croydon ES; Roberts SA; Crosby TD
Int J Radiat Oncol Biol Phys; 2009 Mar; 73(3):818-23. PubMed ID: 18718726
[TBL] [Abstract][Full Text] [Related]
23. Pathological analysis of clinical target volume margin for radiotherapy in patients with esophageal and gastroesophageal junction carcinoma.
Gao XS; Qiao X; Wu F; Cao L; Meng X; Dong Z; Wang X; Gao G; Wu TT; Komaki R; Chang JY
Int J Radiat Oncol Biol Phys; 2007 Feb; 67(2):389-96. PubMed ID: 17236963
[TBL] [Abstract][Full Text] [Related]
24. NeoFLOT: Multicenter phase II study of perioperative chemotherapy in resectable adenocarcinoma of the gastroesophageal junction or gastric adenocarcinoma-Very good response predominantly in patients with intestinal type tumors.
Schulz C; Kullmann F; Kunzmann V; Fuchs M; Geissler M; Vehling-Kaiser U; Stauder H; Wein A; Al-Batran SE; Kubin T; Schäfer C; Stintzing S; Giessen C; Modest DP; Ridwelski K; Heinemann V
Int J Cancer; 2015 Aug; 137(3):678-85. PubMed ID: 25530271
[TBL] [Abstract][Full Text] [Related]
25. Is extended volume external beam radiation therapy covering the anastomotic site beneficial in post-esophagectomy high risk patients?
Yu E; Dar R; Rodrigues GB; Stitt L; Videtic GM; Truong P; Tomiak A; Ash R; Brecevic E; Inculet R; Malthaner R; Vincent M; Craig I; Kocha W; Lefcoe M
Radiother Oncol; 2004 Nov; 73(2):141-8. PubMed ID: 15542160
[TBL] [Abstract][Full Text] [Related]
26. Postoperative Morbidity and Mortality Rates are Not Increased for Patients with Gastric and Gastroesophageal Cancer Who Undergo Preoperative Chemoradiation Therapy.
Badgwell B; Ajani J; Blum M; Ho L; Fournier K; Chiang YJ; Matamoros A; Das P; Mansfield P
Ann Surg Oncol; 2016 Jan; 23(1):156-62. PubMed ID: 26059652
[TBL] [Abstract][Full Text] [Related]
27. The prognostic value of residual nodal disease following neoadjuvant chemoradiation for esophageal cancer in patients with complete primary tumor response.
Blackham AU; Yue B; Almhanna K; Saeed N; Fontaine JP; Hoffe S; Shridhar R; Frakes J; Coppola D; Pimiento JM
J Surg Oncol; 2015 Nov; 112(6):597-602. PubMed ID: 26394724
[TBL] [Abstract][Full Text] [Related]
28. Adjuvant concurrent chemoradiation using intensity-modulated radiotherapy and simultaneous integrated boost for resected high-risk adenocarcinoma of the distal esophagus and gastro-esophageal junction.
Yaremko BP; Palma DA; Erickson AL; Pierce G; Malthaner RA; Inculet RI; Dar AR; Rodrigues GB; Yu E
Radiat Oncol; 2013 Feb; 8():33. PubMed ID: 23398690
[TBL] [Abstract][Full Text] [Related]
29. Survival in Patients With Esophageal Adenocarcinoma Undergoing Trimodality Therapy Is Independent of Regional Lymph Node Location.
Sepesi B; Schmidt HE; Lada M; Correa AM; Walsh GL; Mehran RJ; Rice DC; Roth JA; Vaporciyan AA; Ajani JA; Watson TJ; Swisher SG; Low DE; Hofstetter WL
Ann Thorac Surg; 2016 Mar; 101(3):1075-80; Discussion 1080-1. PubMed ID: 26680311
[TBL] [Abstract][Full Text] [Related]
30. Staging of adenocarcinoma of the gastroesophageal junction.
Parry K; Haverkamp L; Bruijnen RC; Siersema PD; Offerhaus GJ; Ruurda JP; van Hillegersberg R
Eur J Surg Oncol; 2016 Mar; 42(3):400-6. PubMed ID: 26777127
[TBL] [Abstract][Full Text] [Related]
31. Conformal radiotherapy in the adjuvant treatment of gastric cancer: Review of 82 cases.
Kassam Z; Lockwood G; O'brien C; Brierley J; Swallow C; Oza A; Siu L; Knox JJ; Wong R; Cummings B; Kim J; Moore M; Ringash J
Int J Radiat Oncol Biol Phys; 2006 Jul; 65(3):713-9. PubMed ID: 16626887
[TBL] [Abstract][Full Text] [Related]
32. Is preoperative chemotherapy followed by surgery the appropriate treatment for signet ring cell containing adenocarcinomas of the esophagogastric junction and stomach?
Heger U; Blank S; Wiecha C; Langer R; Weichert W; Lordick F; Bruckner T; Dobritz M; Burian M; Springfeld C; Grenacher L; Siewert JR; Büchler M; Ott K
Ann Surg Oncol; 2014 May; 21(5):1739-48. PubMed ID: 24419755
[TBL] [Abstract][Full Text] [Related]
33. Different recurrence pattern after neoadjuvant chemoradiotherapy compared to surgery alone in esophageal cancer patients.
Smit JK; Güler S; Beukema JC; Mul VE; Burgerhof JG; Hospers GA; Plukker JT
Ann Surg Oncol; 2013 Nov; 20(12):4008-15. PubMed ID: 23838922
[TBL] [Abstract][Full Text] [Related]
34. Proposal of a Nomogram for Predicting Survival in Patients with Siewert Type II Adenocarcinoma of the Esophagogastric Junction After Preoperative Radiation.
Liu F; Zhou R; Jiang F; Liu G; Li K; Zhu G
Ann Surg Oncol; 2019 May; 26(5):1292-1300. PubMed ID: 30805805
[TBL] [Abstract][Full Text] [Related]
35. Adenocarcinomas of the esophagogastric junction are more likely to respond to preoperative chemotherapy than distal gastric cancer.
Reim D; Gertler R; Novotny A; Becker K; zum Büschenfelde CM; Ebert M; Dobritz M; Langer R; Hoefler H; Friess H; Schumacher C
Ann Surg Oncol; 2012 Jul; 19(7):2108-18. PubMed ID: 22130620
[TBL] [Abstract][Full Text] [Related]
36. Phase II trial of induction irinotecan-cisplatin followed by concurrent irinotecan-cisplatin and radiotherapy for unresectable, locally advanced gastric and oesophageal-gastric junction adenocarcinoma.
Rivera F; Galán M; Tabernero J; Cervantes A; Vega-Villegas ME; Gallego J; Laquente B; Rodríguez E; Carrato A; Escudero P; Massutí B; Alonso-Orduña V; Cardenal A; Sáenz A; Giralt J; Yuste AL; Antón A; Aranda E;
Cancer Chemother Pharmacol; 2011 Jan; 67(1):75-82. PubMed ID: 20198372
[TBL] [Abstract][Full Text] [Related]
37. Single-institution retrospective comparison of preoperative versus definitive chemoradiotherapy for adenocarcinoma of the esophagus.
Shridhar R; Freilich J; Hoffe SE; Almhanna K; Fulp WJ; Yue B; Karl RC; Meredith K
Ann Surg Oncol; 2014 Nov; 21(12):3744-50. PubMed ID: 24854492
[TBL] [Abstract][Full Text] [Related]
38. Erlotinib and radiation therapy for elderly patients with esophageal cancer - clinical and correlative results from a prospective multicenter phase 2 trial.
Iyer R; Chhatrala R; Shefter T; Yang G; Malhotra U; Tan W; Levea C; Robins M; Khushalani N
Oncology; 2013; 85(1):53-8. PubMed ID: 23860007
[TBL] [Abstract][Full Text] [Related]
39. A phase II trial of induction epirubicin, oxaliplatin, and fluorouracil, followed by surgery and postoperative concurrent cisplatin and fluorouracil chemoradiotherapy in patients with locoregionally advanced adenocarcinoma of the esophagus and gastroesophageal junction.
McNamara MJ; Adelstein DJ; Bodmann JW; Greskovich JF; Ives DI; Mason DP; Murthy SC; Rice TW; Saxton JP; Sohal D; Stephans K; Rodriguez CP; Videtic GM; Rybicki LA
J Thorac Oncol; 2014 Oct; 9(10):1561-7. PubMed ID: 25170643
[TBL] [Abstract][Full Text] [Related]
40. Recursive partitioning analysis of pretreatment variables of 416 patients with locoregional esophageal cancer treated with definitive concomitant chemoradiotherapy on Intergroup and Radiation Therapy Oncology Group trials.
Thomas CR; Berkey BA; Minsky BD; Gaspar LE; Herskovic A; Rich TA; Gunderson LL
Int J Radiat Oncol Biol Phys; 2004 Apr; 58(5):1405-10. PubMed ID: 15050316
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
